BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant ...
Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease May 8, 2026 12:30 PM ...
Experts think certain non-routine tests are worth asking your doctor about, since the results could point to health-saving ...
Participants from partner organizations and Member States tour the Joint FAO/IAEA Centre's agriculture and biotechnology laboratories in Seibersdorf ...
A new analysis has found that plant-based diets reduce a key blood signal of low-level inflammation when tested against diets ...
CRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 proof-of-concept trial in cardiovascular risk planned to ...
Dr. Ellen Romich examines associated vasculitis relapse and which markers signal flare after stopping treatment.
Morning Overview on MSN
Scientific American: Ozempic’s anti-inflammatory effects may be a key win
When large clinical trials of semaglutide, the compound behind Ozempic and Wegovy, began reporting results, the headline ...
BioAge Labs Inc BIOA shares are up on Tuesday after the company reported positive Phase 1 data for BGE-102, an oral NLRP3 inhibitor. Both the 120 mg and newly introduced 60 mg once-daily doses ...
Immunologist Dr. Jenna Macciochi explains that as we age, our immune system starts to decline. Here's how to spot an immune ...
In an era of advanced diagnostics, medical experts stress that accurate diagnosis depends not on the number of tests ...
New guidelines show cholesterol numbers alone don't tell the full story. Here's what doctors say matters most for heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results